Our systems for evaluating new therapies are only as good as the accuracy of the judgements we make about how far patients benefit and how far they feel the burden of side-effects and other drawbacks. In this Editorial we welcome moves on both sides of the Atlantic to include patientsÂ’ own assessments into evaluation procedures, and draw attention to opportunities to engage with these efforts.
Patients who are receiving adequate nutrition have a better prognosis, respond better to chemotherapy and can tolerate higher doses of anticancer treatments. It is therefore important for oncologists to assess and manage malnutrition.
Will pathology services need a serious overhaul if they are to deliver the accuracy required for precision medicine? Two European initiatives are trying to build the case for change in this least visible of cancer disciplines.